Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

B-cell, BAFF, IL-6, biomarker, SLE, biologics, belimumab, mucocutaneous, disease activity, Anifrolumab, LLDAS, DORIS, Remission, LTE

November 2022

Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322

This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.